Knowledge Nugget of the day: Patent evergreening
What is patent evergreening and what does the Indian patent regime tell us about it? Also, go beyond the nugget to know about ...
Gilead to present HIV research findings at conference
Gilead (GILD) announced the upcoming presentation of HIV research findings at the International Congress on Drug Therapy in HIV Infection, ...
pharmaphorum15d
Gilead tries again with twice-yearly HIV drug lenacapavir
Gilead Sciences has refiled for FDA approval of its HIV capsid inhibitor lenacapavir – which only needs to be dosed every six months – after the drug was rejected by the regulator in February.
Business Wire21d
Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral ...
Along with these most recent study results, the potent antiviral activities, and pharmacokinetic profiles of islatravir and lenacapavir support their continued development as an investigational ...
Daily Maverick2d
How South Africa can help secure immediate, global access to HIV prevention drug lenacapavir
We need nothing less than disruptive action to ensure everyone who wants access to affordable lenacapavir can get it.
Gilead Sciences Q3 Earnings Preview: Pipeline shows potential despite near-term challenges
Gilead Sciences (GILD) is scheduled to announce Q3 earnings results on Wednesday, November 6th, after market close. Leerink ...
Hosted on MSN3d
Gilead Sciences Earnings Transcript (NASDAQ:GILD)
The results from the PURPOSE 2 study, which builds on the 100% efficacy shown in PURPOSE 1, demonstrate lenacapavir's ...
Late-Breaking Clinical Data and Real-World Evidence Presented at HIV Glasgow as Gilead Extends Leadership Efforts Toward Ending the Epidemic
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the upcoming presentation of HIV research findings at the International ...
Gilead Sciences, Inc. (GILD) Q3 2024 Earnings Call Transcript
Q3 2024 Earnings Conference Call November 6, 2024 4:30 PM ETCompany ParticipantsDaniel O'Day - Chairman, Chief ...
Gilead Sciences Announces Third Quarter 2024 Financial Results
(Nasdaq: GILD) announced today its third quarter 2024 results of operations. "Gilead’s third quarter results are the strongest of the year to date, with 7% year-over-year revenue growth, including 13% ...